Collegium Pharmaceutical Inc. (COLL) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Collegium Pharmaceutical ... (COLL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

33.15

-0.64 (-1.89%)

At close: Jan 14, 2025, 3:59 PM

33.18

0.09%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	30
Market Cap	1.07B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	2.34
PE Ratio (ttm)	14.17
Forward PE	n/a
Analyst	Buy

Ask	34.79
Volume	204,150
Avg. Volume (20D)	454,775
Open	33.55
Previous Close	33.79
Day's Range	32.65 - 33.99
52-Week Range	28.39 - 42.29
Beta	undefined

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatm...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date May 7, 2015

Employees 197

Stock Exchange NASDAQ

Ticker Symbol COLL

Website https://www.collegiumpharma.com

Analyst Forecast

According to 5 analyst ratings, the average rating for COLL stock is "Buy." The 12-month stock price forecast is $44, which is an increase of 32.73% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Collegium Pharmaceutical Inc. is scheduled to release its earnings on Feb 20, 2025, during market hours.
Analysts project revenue of $179.48M, reflecting a 19.86% YoY growth and earnings per share of 1.5, making a -5.06% decrease YoY.

Why Price Moved

6 days ago · Source

+14.41%

Collegium Pharmaceutical shares are trading higher... Unlock content with Pro Subscription

5 months ago · Source

+10.63%

Collegium Pharmaceutical shares are trading higher after HC Wainwright & Co upgraded the stock from Neutral to Buy announced a price target of $47.

News

1 month ago · seekingalpha.com

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Collegium Pharmaceutical's pain management portfolio, including Xtampza ER and Belbuca, drives 92.8% of revenues, demonstrating its market leadership in abuse-deterrent therapies. The acquisition of J...

2 months ago · zacks.com

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

2 months ago · zacks.com

Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?

Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.

2 months ago · seekingalpha.com

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Danielle Jesse - Director, Investor Relations Michael Heffernan - Interi...

2 months ago · zacks.com

Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings

While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its ...

2 months ago · zacks.com

Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66 per share. This compares to earnings of $1.34 per share a year ago.

2 months ago · zacks.com

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · zacks.com

Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?